Assessment of efficacy and safety by CalliSpheres versus HepaSpheres for drug-eluting bead transarterial chemoembolization in unresectable large hepatocellular carcinoma patients

References

• Bray F, Ferlay J, Soerjomataram I, et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424.
   PubMed Web of Science ®Google Scholar
• Cao WZ, Zhou ZQ, Jiang S, et al. (2019). Efficacy and safety of drug-eluting beads for transarterial chemoembolization in patients with advanced hepatocellular carcinoma. Exp Ther Med 18:4625–30.
   PubMed Web of Science ®Google Scholar
• Chedid MF, Kruel CRP, Pinto MA, et al. (2017). Hepatocellular carcinoma: diagnosis and operative management. Arq Bras Cir Dig 30:272–8.
   PubMed Web of Science ®Google Scholar
• Chen Q, Shu L, Sun Y, et al. (2021). In vitro drug loading, releasing profiles, and in vivo embolic efficacy and safety evaluation of a novel drug-eluting microsphere (CalliSpheres). Cancer Biother Radiopharm;
   Google Scholar
• Chen Q, Sun Y, Dai H, et al. (2020). Assessment of irinotecan loading and releasing profiles of a novel drug-eluting microsphere (CalliSpheres) in vitro. Cancer Biother Radiopharm;
   Google Scholar
• Duan XH, Ju SG, Han XW, et al. (2020). Arsenic trioxide-eluting Callispheres beads is more effective and equally tolerant compared with arsenic trioxide/lipiodol emulsion in the transcatheter arterial chemoembolization treatment for unresectable hepatocellular carcinoma patients. Eur Rev Med Pharmacol Sci 24:1468–80.
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Bellanti F, Villani R, et al. (2017). Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: a meta-analysis of randomized trials. United European Gastroenterol J 5:511–8.
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Serviddio G, Muscatiello N. (2016). Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: a systematic review and meta-analysis. World J Hepatol 8:770–8.
   PubMed Web of Science ®Google Scholar
• Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, et al. (2016). Hepatocellular carcinoma: from diagnosis to treatment. Surg Oncol 25:74–85.
   PubMed Web of Science ®Google Scholar
• Han X, Chen Q, Sun Y, et al. (2019). Morphology, loadability, and releasing profiles of callispheres microspheres in delivering oxaliplatin: an in vitro study. Technol Cancer Res Treat 18:1533033819877989.
   Web of Science ®Google Scholar
• Jordan O, Denys A, De Baere T, et al. (2010). Comparative study of chemoembolization loadable beads: in vitro drug release and physical properties of DC bead and hepasphere loaded with doxorubicin and irinotecan. J Vasc Interv Radiol 21:1084–90.
   PubMed Web of Science ®Google Scholar
• Kadam PD, Chuan HH. (2016). Erratum to: rectocutaneous fistula with transmigration of the suture: a rare delayed complication of vault fixation with the sacrospinous ligament. Int Urogynecol J 27:505.
   PubMed Web of Science ®Google Scholar
• Kucukay F, Badem S, Karan A, et al. (2015). A single-center retrospective comparison of doxorubicin-loaded hepasphere transarterial chemoembolization with conventional transarterial chemoembolization for patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 26:1622–9.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. (2010). Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52–60.
   PubMed Web of Science ®Google Scholar
• Li H, Wu F, Duan M, Zhang G. (2019). Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: a comparison of efficacy and safety. Medicine (Baltimore) 98:e15314.
   PubMed Web of Science ®Google Scholar
• Liang B, Xiang H, Ma C, et al. (2020). Comparison of chemoembolization with CalliSpheres® microspheres and conventional chemoembolization in the treatment of hepatocellular carcinoma: a multicenter retrospective study. Cancer Manag Res 12:941–56.
   PubMed Web of Science ®Google Scholar
• Pinero F, Marciano S, Fernandez N, et al. (2018). Adherence to Barcelona Clinic Liver Cancer therapeutic algorithm for hepatocellular carcinoma in the daily practice: a multicenter cohort study from Argentina. Eur J Gastroenterol Hepatol 30:376–83.
   PubMed Web of Science ®Google Scholar
• Poggi G, Quaretti P, Minoia C, et al. (2008). Transhepatic arterial chemoembolization with oxaliplatin-eluting microspheres (OEM-TACE) for unresectable hepatic tumors. Anticancer Res 28:3835–42.
   PubMed Web of Science ®Google Scholar
• Ren B, Wang W, Shen J, et al. (2019). In vivo evaluation of callispheres microspheres in the porcine renal artery embolization model. Am J Transl Res 11:4166–79.
   PubMed Web of Science ®Google Scholar
• Song MJ, Park CH, Kim JD, et al. (2011). Drug-eluting bead loaded with doxorubicin versus conventional lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients. Eur J Gastroenterol Hepatol 23:521–7.
   PubMed Web of Science ®Google Scholar
• Sun JH, Zhou GH, Zhang YL, et al. (2017). Chemoembolization of liver cancer with drug-loading microsphere 50–100 μm. Oncotarget 8:5392–9.
   PubMedGoogle Scholar
• Wang H, Cao C, Wei X, et al. (2020). A comparison between drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis of six randomized controlled trials. J Cancer Res Ther 16:243–9.
   PubMed Web of Science ®Google Scholar
• Wang CY, Xia JG, Yang ZQ, et al. (2020). Transarterial chemoembolization with medium-sized doxorubicin-eluting Callisphere is safe and effective for patients with hepatocellular carcinoma. Sci Rep 10:4434.
   PubMed Web of Science ®Google Scholar
• Wu B, Zhou J, Ling G, et al. (2018). CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study. World J Surg Oncol 16:69.
   PubMed Web of Science ®Google Scholar
• Xiang H, Long L, Yao Y, et al. (2019). CalliSpheres drug-eluting bead transcatheter arterial chemoembolization presents with better efficacy and equal safety compared to conventional TACE in treating patients with hepatocellular carcinoma. Technol Cancer Res Treat 18:1533033819830751.
   Web of Science ®Google Scholar
• Yang T, Qin W, Sun X, et al. (2020). Efficacy and safety of drug-eluting bead-transcatheter arterial chemoembolization using 100–300 µm versus 300–500 µm CalliSpheres microspheres in patients with advanced-stage hepatocellular carcinoma. J Cancer Res Ther 16:1582–7.
   PubMed Web of Science ®Google Scholar
• Zhang X, Lin X, Qiu H, Peng Z. (2019). An investigation of efficacy, safety, and prognostic factors of drug-eluting beads-transarterial chemoembolization operation with CalliSpheres® microspheres in treating Chinese hepatocellular carcinoma patients. J Clin Lab Anal 33:e22975.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhou J, Zhu DD, et al. (2019). CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study. Clin Transl Oncol 21:167–77.
   PubMed Web of Science ®Google Scholar
• Zhou GH, Han J, Sun JH, et al. (2018). Efficacy and safety profile of drug-eluting beads transarterial chemoembolization by CalliSpheres® beads in Chinese hepatocellular carcinoma patients. BMC Cancer 18:644.
   PubMed Web of Science ®Google Scholar
• Zurstrassen CE, Gireli LPO, Tyng CJ, et al. (2017). Safety and efficacy of HepaSphere 50–100 μm in the treatment of hepatocellular carcinoma. Minim Invasive Ther Allied Technol 26:212–9.
   PubMed Web of Science ®Google Scholar